Health Care Innovation
Drug Prices
NEW STUDY: Creating Two-Part Drug Pricing System Would Ensure Prices More Accurately Reflect How Patients
Establishing a two-part drug pricing system quantifying separate values for a drug’s innovation and production would create an efficient market and a more accurate reflection of how patients value a drug compared to those produced by centralized organizations, argues a new report released today by the Center for Medical Economics ...
Commentary
Drug discount program padding hospital profits
Improving vulnerable populations’ access to medicines is clearly important. But something is amiss when a program that is supposed to improve access to healthcare has turned into a cash cow for hospitals. Yet, that is what has happened to the obscure 340B drug discount program. Too many hospitals across Massachusetts ...
Commentary
Democrats Eye Canada’s Failed Healthcare System – Why?
Democrats in Congress are working to resurrect the Build Back Better Act, their massive social spending proposal that stalled in the Senate last month. To be certain, there’s plenty of disagreement across the party’s moderate and progressive wings. Yet, they’re largely aligned on healthcare. Indeed, Democrats are determined to increase the number ...
Blog
Three Legislative Reforms So Physicians Can Open Hospitals
It is rare to find an issue that unites both political parties. Finding such an issue within healthcare policy is even rarer. However, the worrisome trend of medical care provider consolidation – both individual practitioners and hospitals – concerns everyone. A well-researched fact, consolidation in medical care can dramatically drive ...
Commentary
The FDA needs reform. Biden’s nominee is not the person to do it
By Henry I. Miller, M.S., M.D. and Jeff Stier When President Joe Biden nominated Obama-era Food and Drug Administration Commissioner Dr. Robert Califf to return to his old post, he made what is widely seen as a safe, if uninspired, choice. Califf is a distinguished cardiologist and clinical trial specialist, ...
Commentary
Build Back Better’s Drug Reforms Make American Health Care Worse
Last week, President Joe Biden emphasized the importance of the drug pricing proposals in the Democrats’ roughly $2 trillion Build Back Better spending package. “I think it’s safe to say that all of us, all of us, whatever our age, wherever we live, we can agree that prescription drugs are outrageously expensive ...
Blog
COVID Vaccine Benevolence: An opportunity that US companies and the federal government should seize
Through the brilliance of scientists, the ingenuity of the life sciences industry, and the mobilization of taxpayer dollars, COVID-19 vaccines have been developed and distributed in record time. By now, all American adults who want to be vaccinated have likely received at least two doses, and many three. Supply is ...
Commentary
Comprehensive Regulatory Reform From The Bottom Up: The Case Of 340B
Using the ruse of “price negotiation”, the proponents of the Build Back Better legislation are pushing an ill-fated drug price control plan. Patients will bear exceptionally large costs should their idea of government-directed prices become law. These costs will include lower health outcomes due to reduced access to innovative drugs. ...
Commentary
Misguided Govt Policies Mean Employer-Based Coverage Costs Soar
The cost of employer-based health insurance continues to reach new heights. According to a report out this month from the Kaiser Family Foundation, premiums for a family health plan have risen 47% since 2011, and during that same period, employee earnings rose by 31%, while overall inflation ticked up just 19%. What’s ...
Blog
Could Mark Cuban’s new pharmaceutical venture be a slam dunk?
By Wayne Winegarden and Celine Bookin Billionaire investor Mark Cuban’s pharmaceutical company, the Mark Cuban Cost Plus Drug Company, is hoping to disrupt the pharmaceutical benefit management (PBM) industry with a new venture that seeks to address some of the most criticized practices of the industry. These include PBMs pocketing rather ...
NEW STUDY: Creating Two-Part Drug Pricing System Would Ensure Prices More Accurately Reflect How Patients
Establishing a two-part drug pricing system quantifying separate values for a drug’s innovation and production would create an efficient market and a more accurate reflection of how patients value a drug compared to those produced by centralized organizations, argues a new report released today by the Center for Medical Economics ...
Drug discount program padding hospital profits
Improving vulnerable populations’ access to medicines is clearly important. But something is amiss when a program that is supposed to improve access to healthcare has turned into a cash cow for hospitals. Yet, that is what has happened to the obscure 340B drug discount program. Too many hospitals across Massachusetts ...
Democrats Eye Canada’s Failed Healthcare System – Why?
Democrats in Congress are working to resurrect the Build Back Better Act, their massive social spending proposal that stalled in the Senate last month. To be certain, there’s plenty of disagreement across the party’s moderate and progressive wings. Yet, they’re largely aligned on healthcare. Indeed, Democrats are determined to increase the number ...
Three Legislative Reforms So Physicians Can Open Hospitals
It is rare to find an issue that unites both political parties. Finding such an issue within healthcare policy is even rarer. However, the worrisome trend of medical care provider consolidation – both individual practitioners and hospitals – concerns everyone. A well-researched fact, consolidation in medical care can dramatically drive ...
The FDA needs reform. Biden’s nominee is not the person to do it
By Henry I. Miller, M.S., M.D. and Jeff Stier When President Joe Biden nominated Obama-era Food and Drug Administration Commissioner Dr. Robert Califf to return to his old post, he made what is widely seen as a safe, if uninspired, choice. Califf is a distinguished cardiologist and clinical trial specialist, ...
Build Back Better’s Drug Reforms Make American Health Care Worse
Last week, President Joe Biden emphasized the importance of the drug pricing proposals in the Democrats’ roughly $2 trillion Build Back Better spending package. “I think it’s safe to say that all of us, all of us, whatever our age, wherever we live, we can agree that prescription drugs are outrageously expensive ...
COVID Vaccine Benevolence: An opportunity that US companies and the federal government should seize
Through the brilliance of scientists, the ingenuity of the life sciences industry, and the mobilization of taxpayer dollars, COVID-19 vaccines have been developed and distributed in record time. By now, all American adults who want to be vaccinated have likely received at least two doses, and many three. Supply is ...
Comprehensive Regulatory Reform From The Bottom Up: The Case Of 340B
Using the ruse of “price negotiation”, the proponents of the Build Back Better legislation are pushing an ill-fated drug price control plan. Patients will bear exceptionally large costs should their idea of government-directed prices become law. These costs will include lower health outcomes due to reduced access to innovative drugs. ...
Misguided Govt Policies Mean Employer-Based Coverage Costs Soar
The cost of employer-based health insurance continues to reach new heights. According to a report out this month from the Kaiser Family Foundation, premiums for a family health plan have risen 47% since 2011, and during that same period, employee earnings rose by 31%, while overall inflation ticked up just 19%. What’s ...
Could Mark Cuban’s new pharmaceutical venture be a slam dunk?
By Wayne Winegarden and Celine Bookin Billionaire investor Mark Cuban’s pharmaceutical company, the Mark Cuban Cost Plus Drug Company, is hoping to disrupt the pharmaceutical benefit management (PBM) industry with a new venture that seeks to address some of the most criticized practices of the industry. These include PBMs pocketing rather ...
